Advertisement
UK markets open in 6 hours 27 minutes

  • NIKKEI 225

    37,483.13
    -596.57 (-1.57%)
     

  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     

  • CRUDE OIL

    82.50
    -0.23 (-0.28%)
     

  • GOLD FUTURES

    2,388.70
    -9.30 (-0.39%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • Bitcoin GBP

    50,793.85
    +1,679.56 (+3.42%)
     

  • CMC Crypto 200

    1,303.12
    +417.58 (+46.72%)
     

  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     

  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

J&J and Bavarian Nordic start clinical tests of Ebola vaccine

Reuters - UK Focus

LONDON, Jan 6 (Reuters) - U.S. drugmaker Johnson & Johnson (NYSE: JNJ - news) said on Tuesday it had started clinical trials of its experimental Ebola vaccine, which uses a booster developed by Denmark's Bavarian Nordic (Other OTC: BVNKF - news) .

The initiation of the Phase I tests, which had been expected about now, marks further progress in the race to develop a shot against a disease that has killed more than 8,000 people in West Africa since last year.

Two other experimental vaccines, one from GlaxoSmithKline (Swiss: GSK.SW - news) and a rival from NewLink and Merck (Other OTC: MKGAF - news) , are already in clinical development.

(Reporting by Ben Hirschler, editing by Louise Heavens)